Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.240
-0.070 (-5.34%)
At close: Sep 11, 2026, 4:00 PM EDT
1.220
-0.020 (-1.61%)
After-hours: Sep 11, 2026, 8:00 PM EDT
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
3.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
| Dec 31, 2021 | 449.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 60 Degrees Pharmaceuticals | 1.21M |
| SciSparc | 856.00K |
| GeoVax Labs | 852.28K |
| Onconetix | 645.82K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 136.51K |
| Silo Pharma | 54.08K |
CLDI News
- 4 days ago - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - GlobeNewsWire
- 7 weeks ago - Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewsWire
- 7 weeks ago - Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - GlobeNewsWire